Viridian Therapeutics, Inc./DE (VRDN) Free cash flow 2016–2025
Viridian Therapeutics, Inc./DE (VRDN) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$276.9MFY2025 · since FY2016: -$15.0M → -$276.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$276.9M | -18.9% |
| FY2024 | -$232.8M | -25.8% |
| FY2023 | -$185.1M | -95.6% |
| FY2022 | -$94.6M | -72.3% |
| FY2021 | -$54.9M | -84.2% |
| FY2020 | -$29.8M | +17.5% |
| FY2019 | -$36.1M | -32.4% |
| FY2018 | -$27.3M | +4.0% |
| FY2017 | -$28.4M | -89.4% |
| FY2016 | -$15.0M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice